UR Medicine Faculty
The University of Rochester Medical Faculty Group
(URMFG) consists of over 900 specialist and primary care providers spanning 19
departments.
URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner
Accountable Health Partners (AHP) is a network of
over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the
region. AHP offers a full range of care.
I chose this specialty because I have always had an interest in diseases of the blood. My patients can be confident knowing I provide optimal individual patient care based on precision diagnosis and targeted therapy. Although I treat many types of blood diseases, my area of expertise is chronic lymp...
I chose this specialty because I have always had an interest in diseases of the blood. My patients can be confident knowing I provide optimal individual patient care based on precision diagnosis and targeted therapy. Although I treat many types of blood diseases, my area of expertise is chronic lymphocytic leukemia.
Internship, Internal Medicine, Coronation Hospital (South Africa). 1984 - 1984
Education
MBBCH | University of Witwatersrand (South Africa).1983
Awards
Hematology Teacher of the Year.2023 - 2024
Teacher of the Year in Hematology.2008
Kaminer Fellowship (Travel Award).1995
Degree with Distinction.1983
Research
Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complica...
Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.
Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M
Leukemia & lymphoma.. 2022 December 63 (13):3021-3031. Epub 09/07/2022.
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leukemia research.. 2022 October 121 :106943. Epub 09/02/2022.
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leukemia research.. 2022 September 120 :106919. Epub 07/18/2022.
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C
Haematologica.. 2018 September 103 (9):1511-1517. Epub 06/07/2018.
Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE
American journal of hematology.. 2014 July 89 (7):757-65. Epub 04/26/2014.
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A
American journal of hematology.. 2013 May 88 (5):375-8. Epub 03/19/2013.
Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphpocytic leukemia
Shanafelt, TD; Call, TG; Zent, CS; Leis, JF; LaPlant, B; Bowen, DA; Roos, M; Laumann, K; Ghosh, AK; Lesnick, C; Lee, MJ; Yang, CS; Jelinek, DF; Erlichman, C; Kay, NE.
Cancer. 2013; 119(2): 363-70.
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphpocytic leukemia with alemtuzumab and rituximab
Multi-parameter prognostication in chronic lymphocytic leukemia
Zent CS.
Leuk Lymphoma. 2011; 52(10): 1823-4.
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance
Cytometry B Clin Cytom. 2010; 58(Suppl 1): S35-41.
A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia
Van Dyke DL; Shanafelt TD; Call TG; Zent CS; Smoley SA; Rabe KG; Schwager SM; Sonbert JC; Slager SL; Kay NE.
Br J Haematol. 2010; 148(4): 544-50.
Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications
Zent CS; Van Dyke DL.
Leuk Lymphoma. 2010; 51(2): 186-7.
Autoimmune complications in chronic lymphocytic leukaemia (CLL)
Zent CS; Kay NE.
Best Pract Res Clin Haematol. 2010; 23(1): 47-59.
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone
Bowen DA; Call TG; Shanafelt TD; Kay NE; Schwager RM; Reinalda MS; Rabe KG; Slager SL; Zent CS.
Leuk Lymphoma. 2010; 51(4): 620-7.
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
Management of autoimmune cytopenia complicating chronic lymphocytic leukemia
Zent CS; Shanafelt T.
Leuk Lymphoma. 2009; 50(6): 863-4.
Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis
Zent CS; Ding W; Reinalda MS; Schwager SM; Hoyer JD; Bowen DA; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Kay NE; Slager SL.
Leuk Lymphoma. 2009; 50(8): 1261-8.
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia
Shanafelt TD; Call TG; Zent CS; LaPlant B; Bowen DA; Roos M; Secreto CR; Ghosh AK; Kabat BF; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE.
J Clin Oncol. 2009; 27(23): 3808-14.
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia
CD49d expression is an independent predictor of overall survival i npatients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
Shanafelt TD; Geyer SM; Bone ND; Tschumper RC; Witzig TE; Nowakowski GS; Zent CS; Call TG; Laplant B; Dewald GW; Jelinek DF; Kay NE.
Br J Haematol. 2008; 140(5): 537-46.
Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma
Hogan WJ; Zent CS.
Leuk Lymphoma. 2008; 49(5): 835-6.
The prognostic significant of cytopenia in chronoc lymphocytic leukaemia/small lymphocytic lymphoma
Zent CS; Ding W; Schwager SM; Reinalda MS; Hoyer JD; Jelinek DF; Tschumper RC; Bowen DA; Call TG; Shanafelt TD; Kay NE; Slager SL.
Br J Haematol. 2008; 141(5): 615-21.
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count , greater than or equal to 5 x 10e9/L but a B-cell lymphocyte count less than or equal to 5 x 10e9/L?
Shanafelt TD; Kay NE; Cell TG; Zent CS; Jelinek DF; LaPlant B; Morice WG; Hanson CA.
Leuk Res. 2008; 32(9): 1458-61.
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
Zent CS; Call TG' Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE.
Cancer. 2008; 113(8): 2110-8.
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE.
Leuk Res. 2008; 32(12): 1849-56.
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC.
Blood. 2007; 109(2): 405-11.
Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72 year old: report of a case
Rockacy J; Viozzi CF; Zent CS.
J Oral Maxillofac Surg. 2007; 65(2): 333-7.
Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma
Ding W; Zent CS.
Clin Adv Hematol Oncol. 2007; 5(4): 257-61.
Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test
Nowakowski GS; Hoyer JD; Shanafelt, TD; Geyer, SM; LaPlant BR; Call TG; Jelinek DF; Zent CS; Kay NE.
Mayo Clin Proc. 2007; 82(4): 449-53.
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE.
Cancer. 2007; 109(11): 2291-8.
Chronic lymphocytic leukemia: biology and current treatment
Zent CS; Kay NE.
Curr Oncol Rep. 2007; 9(5): 345-52.
Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients
Shanafelt TD; Bowen D; Venkat C; Slager SL; Zent CS; Kay NE; Reinalda M; Sloan JA; Call TG.
Br J Haematol. 2007; 139(2): 255-64.
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia
Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD.
Br J Haematol. 2007; 139(3): 398-404.
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
Bowen DA; Call TG; Jenkins GD; Zent CS; Schwager SM; Van Dyke DL; Jelinek DF; Kay NE; Shanafelt TD.
Leuk Lymphoma. 2007; 48(12): 2412-7.
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
Browning RL; Geyer SM; Johnson AJ; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Zent CS; Bone ND; Dewald GW; Lin TS; Heerema NA; Gever MR; Kay NE; Byrd JC; Lucas DM.
Leuk Res. 2007; 49(1): 49-56.
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia
Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies
Shanafelt TD; Lee YK; Call TG; Nowakowski GS; Dingli D; Zent CS; Kay NE.
Leuk Res. 2005; 30(6): 707-12.
Update on monoclonal antibody therapy in chronic lymphocytic leukemia
Zent CS; Kay NE.
Clin Adv Hematol Oncol. 2004; 2(2): 107-13.
The academic hematology-oncology firm: a model for postgraduate cancer education
Kohli M; Zent C; Hutchins LF; Safar M; Dotson P; Mehta P.
J Cancer Educ. 2004; 19(1): 45-9.
Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death
Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia
Zent CS; Kay NE.
Curr Oncol Rep. 2004; 6(5): 348-54.
Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma
Kyasa MJ; Parrish RS; Schichman SA; Zent CS.
Am J Hematol. 2003; 74(1): 1-8.
The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype
Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer
Kohli M; Fink LM; Spencer JH; Zent CS.
Blood Coagul Fibrinolysis. 2002; 13(1): 1-5.
Linezolid-induced pure red blood cell aplasia
Monson T; Schichman SA; Zent CS.
Clin Infect Dis. 2002; 35(3): E29-31.
Anemia and chronic disease
Zent C.
US Medicine. 2001; 37(5 Suppl): 5-8.
Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data
Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies
Zent C; Rowley JD; Nucifora G.
Leukemia. 1997; 3(11 Suppl): 273-8.
Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression nof co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigneic properties
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G.
Current Topics in Microbiology & Immunology. 1996; 211: 243-52.
The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G.
Proc Natl Acad Sci. 1996; 93(3): 1044-8.
Toxicity of anti-tuberculous medication
Zent CS.
S. Afr J of Epidemiology and Infection. 1994; 9(1): 5-9.
Drug allergy
Zent C, Smith P.
S AFr Med J. 1994; 84(5): 281-286.
Prediction of amikacin dose requirements in neutropenic patients with haematological disease
Zent CS, Allin R, Folb PI.
S. Afr Med J. 1993; 82(11): 853-854.
Books
ASH-SAP American Society of Hematology Self-Assessment Program
(2016)
Interferons: biological activities and clinical efficacy
(1997)
Chapter: Treatment options for hairy cell leukemia
Authors: Zent CS and Golomb HM
Publisher:
Springer, Berlin 1997
The Chemotherapy Source Book
(1996)
Chapter: Acute leukmia in adults
Authors: Zent CS, Larson RA
Publisher:
Williams and Wilkins, Baltimore, MD 1996
Current Therapy in Hematology-Oncology
(1995)
Chapter: Hairy Cell Leukemia
Authors: Zent CS, Golomb HM
Publisher:
Mosby, St. Louis, MO 1995
South African National Formulary
(1995)
Chapter: Anti-infectives for systemic use
Authors: Zent CS
Publisher:
MASA, Cape Town 1995
Ratings & Comments
At URMC, we believe that patients should be empowered to make the right decisions regarding their
personal
healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all
aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying
star ratings for our providers along with anonymous patient comments on our website. This will help you make
better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used
to generate this vital information. Learn more about
our survey process.
Ratings
Concern the care provider showed for your questions or worries
5.0 stars
Care provider's efforts to include you in decisions about your care
4.9 stars
Explanations the care provider gave you about your problem or condition
4.9 stars
Likelihood of recommending this care provider to others
5.0 stars
Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)
5.0 stars
Patient Comments
Provider is - as always- courteous, professional, concerned and highly competent. I always leave the visit assured that I am in e cell et hands in regard to my [...] management.
Dec 18, 2024
My doctor is terrific! He makes me feel comfortable with his complete explanation of my tests, treatments and general health. I would highly recommend him to everyone and I have talked about him to all of my family and friends. He is the best doctor I have ever had.
Dec 14, 2024
Dr Zent is fabulous! He is caring, personable and knowledgeable.
Nov 16, 2024
Both Dr. Mannava and Dr. Zent are consistently good listeners, and always treat my concerns with respect and answer my questions
Nov 10, 2024
Dr Zent is the best
Nov 01, 2024
5.0 stars
Dr. Zent and Sharon are the best!
Oct 31, 2024
5.0 stars
Excellent visit
Oct 26, 2024
5.0 stars
I am very impressed with Dr. Zent. He's very thorough and thoughtful. I have 100% trust in him.
Oct 20, 2024
5.0 stars
It was evident that both Drs. Zent and Usmann and nurse Sharon had thoroughly read my file and were quite familiar with my history and current needs.
Oct 20, 2024
5.0 stars
Dr. Zent And his staff are superb
Oct 18, 2024
5.0
Dr. Zent is always concerned and attentive.
Oct 10, 2024
5.0
Very thorough exam & explanation
Oct 04, 2024
5.0
Dr. Zent was excellent in answering all our questions concerning my condition. He explained all the variables and the care needed at this time. Dr. Zent is an asset to the UR Medicine.
Sep 24, 2024
5.0
Dr. Zent took the time to listen to situation, and didn't pressure me to take specific vaccines which I appreciated. [...]
Sep 23, 2024
5.0
Dr. Zent was awesome!
Sep 16, 2024
5.0
Dr Zent is great. As a follow physician, I could tell how knowledgeable he was. Superb clinician that instantly gains your trust.
Sep 03, 2024
5.0
Dr. Zent is tops.
Sep 02, 2024
5.0
Dr. Zent is wonderful!
Aug 28, 2024
5.0
I am blessed to have such a knowledgeable, caring and professional doctor!!
Jun 30, 2024
5.0
In addition to my regular CLL checkup, I asked questions about prescriptions given by Urgent Care and about protection from insect stings. Dr. Zent always provides common sense answers and advice. He and his staff care are professional, and up to date on care for my needs.
Jun 11, 2024
5.0
Dr. Zent is outstanding. I feel very fortunate that he is my specialist.
May 09, 2024
5.0
Doctor Zent is a good physician I am glad he was recommended for my Oncologist.
May 04, 2024
5.0
I drive 5 hours [...] because Dr. Zent is the best
Apr 20, 2024
5.0
Dr. Zent is always thorough in explaining my health conditions and answer our questions.
Apr 08, 2024
4.6
Even though it was a most unusual day, my provider did not rush through the appointment.
Feb 21, 2024
5.0
Definitely would recommend Dr. Zent
Jan 24, 2024
5.0
Have recommended this provider and his team. You can't get any better care
Nov 23, 2023
5.0
I consider myself fortunate to have Dr Zent providing my care.
Nov 20, 2023
5.0
Dr. Zent saved my life
Nov 09, 2023
5.0
Dr. Zent is always willing to discuss my illness and treatment options in as much detail and depth as I request, including waiting for me to catch up when I'm taking notes.
Nov 04, 2023
5.0
Dr. Zent is an excellent doctor who provides very good care to his patients.
Aug 14, 2023
5.0
Excellent care
Jul 20, 2023
5.0
He is very good at what he does.
Jul 18, 2023
5.0
Dr. Zent considers the entire constellation of a person's health issues while monitoring CLL In my case it consists of comorbidities with MS and metastatic prostate cancer. I find it especially reassuring that he looks at the whole picture. He listens carefully and I never feel rushed. He patiently provides advice and explanations.
Jun 28, 2023
5.0
Dr. Zent is the most knowledgeable kindest doctor in the whole world
Jun 25, 2023
5.0
Dr. Zent is an exceptional doctor. I am very satisfied with the care he provides.
Jun 25, 2023
5.0
Dr. Zent always asks if you have any questions regarding what he is telling you.
Apr 07, 2023
5.0
Great drs. great staff.
Feb 14, 2023
4.2
I do not recommend.
Feb 13, 2023
3.8
Explanation sometimes became very technical.
Dec 17, 2022
5.0
Provider is of high quality
Nov 12, 2022
5.0
Always an excellent experience in the office, and always (during the work week) prompt replies to my questions through the portal. But I have to say I spent a very anxious weekend after this last visit because a question I sent on the portal wasn't replied to until Monday morning, I understand... but It was rough.
Oct 28, 2022
5.0
Excellent Care
Oct 14, 2022
5.0
Everything went very smoothly as expected.
Oct 05, 2022
5.0
Great experience
Sep 27, 2022
5.0
Really liked Dr Zent. Explained everything, very easy to understand. Showed real concern for issues
Sep 25, 2022
5.0
Saved my life.
Aug 17, 2022
5.0
Dr. Zent really cares about his patients.
Jul 21, 2022
5.0
The best doctor in the whole world
Jul 21, 2022
5.0
We are VERY FORTUNATE to have Dr. Zent on staff at WILMOT!!!
Jun 17, 2022
5.0
Dr Zent is excellent as my health care provider
Jun 15, 2022
5.0
Dr. Zent is an excellent doctor.
May 06, 2022
4.6
Dr. Zent and I had both researched the same new treatment and concluded it was not right for me, also he diagnosed a skin issue that had been misdiagnosed by my Dermatologist so I will be switching to the dermatologist who works with Dr Zent's patients (Dr. Manavva). We decided based on the experience between the last two treatments that we need to move them closer together. All decisions were very collaborative, and I felt like he listened with respect to my opinions and feedback.
Mar 24, 2022
5.0
Dr. Zent is one of two doctors I've had in my life who I consider top of their field. He is concerned with my whole health [...].
Mar 01, 2022
5.0
Dr. Zent is an excellent doctor, very knowledgeable and caring.
